Navigation Links
PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress

PARIS and NES-ZIONA, Israel, July 10, 2012 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), announced that the company will present data today on its long-acting clotting factors for the treatment of hemophilia at the World Federation of Hemophilia (WFH) World Congress.  PROLOR scientist Dr. Gili Hart will discuss data from preclinical studies of PROLOR's long-acting versions of Factor VIIa (Factor Vlla-CTP) and Factor lX (Factor IX-CTP) in two posters at the Congress. 

Top-line results of these studies were previously reported by PROLOR.  They showed that in hemophilic mouse models, PROLOR's long-acting Factor VIIa-CTP and Factor IX-CTP demonstrated superior performance on multiple measures of clotting efficacy compared to commercially available Factor VIIa and Factor IX, including survival following a bleeding challenge,  generation of the pro-clotting enzyme thrombin, duration of clotting activity and number of spontaneous re-occurring bleeding episodes. 

PROLOR CEO Dr. Abraham Havron commented, "The WFH World Congress is a comprehensive meeting that brings together leading researchers, physicians and patient representatives committed to improved therapies for hemophilia.  We are pleased to have the opportunity to present the promising data from preclinical studies of our long-acting clotting factors to these opinion leaders as we advance them towards human clinical studies."

The posters,"F VIIa-CTP and F IX-CTP are novel long-acting coagulation factors with prolonged hemostatic activity in hemophilic animal models," Hart G, Monahan P, Seligsohn U, Zakar M, Hershkovitz O, Bar-Ilan A, Fima E, will be presented today at the WFH World Congress in Paris, France.

The biannual WFH World Congress is the largest global event focusing on bleeding disorders and features presentations, workshops and exhibits on cutting-edge trends in research and treatment for hemophilia and other inherited bleeding disorders.  Participants include doctors, scientists, healthcare workers, people with bleeding disorders and hemophilia organizations.
The Congress is being held from July 8- July 12, 2012.  For more information, visit PROLOR PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP technology, primarily to develop longer-acting proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales.  The CTP technology is applicable to virtually all proteins.  PROLOR is currently developing a long-acting version of human growth hormone, which has successfully completed a Phase II clinical trial.  It also is developing long-acting versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity, all of which are in preclinical development.  For more information, visit

 Safe Harbor Statement:  This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding the results of current clinical studies and preclinical experiments and the effectiveness of PROLOR's long-acting protein programs, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.PROLOR CONTACT:MEDIA CONTACT:Shai Novik, PresidentBarbara LindheimPROLOR Biotech, Inc.BLL Partners, LLCTel: +1 866 644-78+1 212 584-2276Email:

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
2. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 2011
3. Puma Biotechnology Announces Completion of Private Placement
4. Animal Biotechnology - Technologies, Markets and Companies
5. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug
6. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
7. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-32765
8. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
9. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
10. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
(Date:12/1/2015)... Texas (PRWEB) , ... December ... ... , a leading relationship marketing company specializing in scientifically backed, age-defying products, ... January 2016 issue, which highlights the exponential success and unrivaled opportunities that ...
(Date:12/1/2015)... DIEGO , December 1, 2015 Dr. Harry Lander ... serving as Chief Science Officer and recruits ... Dr. Harry Lander , President of Regen, expands his role to ... and recruits five distinguished scientists to join ... Regen, expands his role to include serving ...
(Date:12/1/2015)... ) has ... Virology and Bacteriology Testing Market: Sales and ... Shares by Test, Innovative Technologies, Competitive Strategies, ... --> ) has announced the ... Bacteriology Testing Market: Sales and Volume Segment ...
(Date:11/30/2015)... MIAMI (PRWEB) , ... November 30, 2015 , ... ... opening of a new, Good Manufacturing Practice (GMP) 10000 in the Santiago Marriott. ... technologies available, and is operated by a world-class team of qualified medical researchers ...
Breaking Biology Technology:
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):